Abstract
Melatonin, an indolamine derived from the amino-acid tryptophan, participates in diverse physiological functions and has great functional versatility related to the regulation of circadian rhythms and seasonal behaviour, sexual development, retinal physiology, tumour inhibition, as an antioxidant, immunomodulatory and anti-aging properties. In relation to its oncostatic properties, there is evidence that tumor initiation, promotion or progression may be restrained by the night-time physiological surge of melatonin in the blood or extracellular fluid. In addition, depressed nocturnal melatonin concentrations or nocturnal excretion of the main melatonin metabolite, 6-sulfatoxymelatonin, were found in individuals with various tumor types. In the majority of studies, melatonin was shown to inhibit development and/or growth of various experimental animal tumors and some human cell lines in vitro. Many tumors do not respond to drug treatment due to their resistance to undergo apoptosis thereby contributing to the development of cancer. Thus, given the importance of the apoptotic program in cancer treatment, the role of melatonin in influencing apoptosis in tumor cells attracted attention because it seems that it actually promotes apoptosis in most tumor cells, in contrast to the obvious inhibition of apoptotic processes in normal cells. Thus, this paper is also intended to provide to the reader an up-date of all the researches that have been carried out to date, which investigate the proapoptotic effects of melatonin in experimental preclinical models of cancer (in vitro and in vivo) and the underlying proposed action mechanism of this effects. If melatonin uniformly induces apoptosis in cancer cells, the findings could have important clinical implications to improve the quality of live while preventing the appearance of cancer.
Keywords: Apoptosis, cancer cells, cancer therapy, caspase activation, cell cycle, cell death, extrinsic apoptotic pathway, intrinsic apoptotic pathway, melatonin, tumor.
Current Medicinal Chemistry
Title:Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Volume: 19 Issue: 22
Author(s): M. Sánchez-Hidalgo, J. M. Guerrero, I. Villegas, G. Packham and C. A. de la Lastra
Affiliation:
Keywords: Apoptosis, cancer cells, cancer therapy, caspase activation, cell cycle, cell death, extrinsic apoptotic pathway, intrinsic apoptotic pathway, melatonin, tumor.
Abstract: Melatonin, an indolamine derived from the amino-acid tryptophan, participates in diverse physiological functions and has great functional versatility related to the regulation of circadian rhythms and seasonal behaviour, sexual development, retinal physiology, tumour inhibition, as an antioxidant, immunomodulatory and anti-aging properties. In relation to its oncostatic properties, there is evidence that tumor initiation, promotion or progression may be restrained by the night-time physiological surge of melatonin in the blood or extracellular fluid. In addition, depressed nocturnal melatonin concentrations or nocturnal excretion of the main melatonin metabolite, 6-sulfatoxymelatonin, were found in individuals with various tumor types. In the majority of studies, melatonin was shown to inhibit development and/or growth of various experimental animal tumors and some human cell lines in vitro. Many tumors do not respond to drug treatment due to their resistance to undergo apoptosis thereby contributing to the development of cancer. Thus, given the importance of the apoptotic program in cancer treatment, the role of melatonin in influencing apoptosis in tumor cells attracted attention because it seems that it actually promotes apoptosis in most tumor cells, in contrast to the obvious inhibition of apoptotic processes in normal cells. Thus, this paper is also intended to provide to the reader an up-date of all the researches that have been carried out to date, which investigate the proapoptotic effects of melatonin in experimental preclinical models of cancer (in vitro and in vivo) and the underlying proposed action mechanism of this effects. If melatonin uniformly induces apoptosis in cancer cells, the findings could have important clinical implications to improve the quality of live while preventing the appearance of cancer.
Export Options
About this article
Cite this article as:
Sánchez-Hidalgo M., Guerrero M. J., Villegas I., Packham G. and de la Lastra A. C., Melatonin, A Natural Programmed Cell Death Inducer in Cancer, Current Medicinal Chemistry 2012; 19 (22) . https://dx.doi.org/10.2174/092986712801661013
DOI https://dx.doi.org/10.2174/092986712801661013 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells
Current Medicinal Chemistry TRP Channels as A Newly Emerging Non-Voltage-Gated Ca2+ Entry Channel Superfamily
Current Pharmaceutical Design Radiopharmaceutical: Revolutionary Agents for Diagnosis
Current Radiopharmaceuticals (Review Article) Screening for Disease-Markers and Investigating Drug Effects by Proteome Profiling: Can it Meet Expectations?
Combinatorial Chemistry & High Throughput Screening Synergistic Approaches to Clinical Oncology Biomarker Discovery
Current Topics in Medicinal Chemistry Studies on Anticancer Activities of Lactoferrin and Lactoferricin
Current Protein & Peptide Science The Ca2+-Activated K+ Channel of Intermediate Conductance:A Molecular Target for Novel Treatments?
Current Drug Targets Novel Glitazones with Diverse Peroxisome Proliferator Activated Receptor Modulatory Potential
Current Bioactive Compounds Editorial [Hot Topic: Cancer Vaccine and Immunotherapy (Executive Editor: Farid Saleh)]
Current Pharmaceutical Design Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets Intravesical Therapy of Superficial Bladder Cancer
Current Pharmaceutical Design Increased Production of Recombinant O-Phospho-L-Serine Sulfhydrylase from the Hyperthermophilic Archaeon Aeropyrum pernix K1 Using Escherichia coli
Current Biotechnology Evolution of the Strategies for Screening and Identifying Human Tumor Antigens
Current Protein & Peptide Science Principles of an Adenovirus-Based Assay for Candidate Compounds with Broad Spectrum of Anti-Neoplastic Activities
Letters in Drug Design & Discovery Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children
Current Drug Metabolism Modulation of the Ceramide Level, A Novel Therapeutic Concept
Current Drug Targets Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry From Natural Products to Small Molecule Ketone Histone Deacetylase Inhibitors: Development of New Class Specific Agents
Current Pharmaceutical Design Delta Np63 alpha – Responsive microRNA Modulate the Expression of Metabolic Enzymes
Current Pharmaceutical Biotechnology Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer
Anti-Cancer Agents in Medicinal Chemistry